Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)

NCT00775411 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Choroidal Neovascularization
Age-Related Maculopathy

Interventions

DRUG: dexamethasone
BIOLOGICAL: ranibizumab

Sponsor

Allergan